Business Description
Beximco Pharmaceuticals Ltd
ISIN : BD0453BXPH04
Description
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 1.3 | |||||
| Interest Coverage | 6.93 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.37 | |||||
| Beneish M-Score | -2.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.3 | |||||
| 3-Year EBITDA Growth Rate | 17.1 | |||||
| 3-Year EPS without NRI Growth Rate | 9.1 | |||||
| 3-Year FCF Growth Rate | 1.1 | |||||
| 3-Year Book Growth Rate | 10.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.43 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.23 | |||||
| 9-Day RSI | 50.88 | |||||
| 14-Day RSI | 48.04 | |||||
| 6-1 Month Momentum % | -23.8 | |||||
| 12-1 Month Momentum % | -23.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | |||||
| Quick Ratio | 0.72 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 267.63 | |||||
| Days Sales Outstanding | 39.91 | |||||
| Days Payable | 71.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.96 | |||||
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | 36.9 | |||||
| Forward Dividend Yield % | 2.96 | |||||
| 5-Year Yield-on-Cost % | 10.7 | |||||
| Shareholder Yield % | 9.15 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 43.63 | |||||
| Operating Margin % | 18.23 | |||||
| Net Margin % | 11.83 | |||||
| FCF Margin % | 8.32 | |||||
| ROE % | 8.49 | |||||
| ROA % | 5.42 | |||||
| ROIC % | 7.05 | |||||
| ROC (Joel Greenblatt) % | 10.5 | |||||
| ROCE % | 10.08 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14 | |||||
| PE Ratio without NRI | 14 | |||||
| Shiller PE Ratio | 13.81 | |||||
| Price-to-Owner-Earnings | 45.12 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 1.65 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 1.29 | |||||
| Price-to-Free-Cash-Flow | 19.88 | |||||
| Price-to-Operating-Cash-Flow | 13.53 | |||||
| EV-to-EBIT | 10.32 | |||||
| EV-to-EBITDA | 10.32 | |||||
| EV-to-Forward-EBITDA | 6.77 | |||||
| EV-to-Revenue | 1.84 | |||||
| EV-to-Forward-Revenue | 1.69 | |||||
| EV-to-FCF | 22.17 | |||||
| Price-to-Projected-FCF | 0.89 | |||||
| Price-to-DCF (Earnings Based) | 0.57 | |||||
| Price-to-DCF (FCF Based) | 1.72 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.71 | |||||
| Price-to-Graham-Number | 0.8 | |||||
| Earnings Yield (Greenblatt) % | 9.69 | |||||
| FCF Yield % | 5.03 | |||||
| Forward Rate of Return (Yacktman) % | 12.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beximco Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil BDT) | 31,925.243 | ||
| EPS (TTM) (BDT) | 8.46 | ||
| Beta | 0 | ||
| Volatility % | 16.32 | ||
| 14-Day RSI | 48.04 | ||
| 14-Day ATR (BDT) | 2.554924 | ||
| 20-Day SMA (BDT) | 118.515 | ||
| 12-1 Month Momentum % | -23.8 | ||
| 52-Week Range (BDT) | 110 - 146.2 | ||
| Shares Outstanding (Mil) | 446.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beximco Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beximco Pharmaceuticals Ltd Stock Events
| Event | Date | Price(BDT) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beximco Pharmaceuticals Ltd Frequently Asked Questions
What is Beximco Pharmaceuticals Ltd(DHA:BXPHARMA)'s stock price today?
The current price of DHA:BXPHARMA is BDT118.40. The 52 week high of DHA:BXPHARMA is BDT146.20 and 52 week low is BDT110.00.
When is next earnings date of Beximco Pharmaceuticals Ltd(DHA:BXPHARMA)?
The next earnings date of Beximco Pharmaceuticals Ltd(DHA:BXPHARMA) is 2024-07-30 Est..
Does Beximco Pharmaceuticals Ltd(DHA:BXPHARMA) pay dividends? If so, how much?
The Dividend Yield %  of Beximco Pharmaceuticals Ltd(DHA:BXPHARMA) is 2.96% (As of Today), Highest Dividend Payout Ratio of Beximco Pharmaceuticals Ltd(DHA:BXPHARMA) was 0.41. The lowest was 0.09. And the median was 0.19. The  Forward Dividend Yield % of Beximco Pharmaceuticals Ltd(DHA:BXPHARMA) is 2.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers